A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease (NCT06079190)
Progress-AD
This trial is Currently recruiting
Registration number NCT06079190
Program & service
This trial is being run with the Brain service, and as part of the Brain program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principle investigator
Associate Professor David Darby
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.